论文部分内容阅读
恶性淋巴瘤已为可治愈的疾病,但仍有部分病例对常规治疗反应不佳。增大放、化疗剂量或可提高疗效,但又可致骨髓造血功能衰竭。因此国内外已广泛利用自体骨髓移植(ABMT)来保证放、化疗剂量的提高。ABMT有两种,一为冷藏(4℃保存)骨髓应用,一为冻存(多为-196℃液氮中)骨髓应用。前者简便易行,但保存时间只有48～72小时,不易适时安排合理充分的放、化疗,影响了疗效的提高。我们在冷藏骨髓应用与骨髓冻存研究的基础上,开展了冻存ABMTT作。谨将3例晚期淋巴瘤患者的应用情况初步小结于下。 材料 3例均系病理学检查确诊的恶性淋巴瘤Ⅲ至Ⅳ期病例,见表1。
Malignant lymphoma has become a curable disease, but some cases still respond poorly to conventional treatment. Increase radiotherapy, chemotherapy dose or can improve the efficacy, but can cause bone marrow hematopoietic failure. Therefore, extensive use of autologous bone marrow transplantation (ABMT) at home and abroad to ensure that the release of chemotherapy dose increase. There are two ABMTs, one for cryogenic (4 ° C preservation) bone marrow applications and one for cryopreservation (mostly liquid nitrogen at -196 ° C) bone marrow applications. The former is simple and convenient, but the preservation time is only 48 ~ 72 hours, it is not easy to arrange a reasonable full radiotherapy and chemotherapy, affecting the improvement of the curative effect. We conducted cryopreservation of ABMTT on the basis of a review of cryogenic bone marrow applications and bone marrow cryopreservation. Would like to three cases of patients with advanced lymphoma preliminary summary of the situation below. Materials 3 cases were confirmed by pathological examination of malignant lymphoma Ⅲ to Ⅳ cases, see Table 1.